Interactive Powerpoint_How to Master effective communication
Pharmacovigilance for ASU Drugs
1. Dr. Prajeesh Nath E N
PG Dept. of Rasasastra & Bhaishajya Kalpana
Amrita School of Ayurveda
2. Content
Etymology and Definition.
Historical Background.
Aims of Pharmacovigilance.
Pharmacovigilance in India.
National Pharmacovigilance Programme for ASU.
Reporting Culture.
Ayurvedic concept of PV.
Need of PV for Ayurvedic Medicines.
Challenges in introducing PV in Ayurveda.
15/1/2014
Dr. Prajeesh nath, ASA
2
3. Etymology and Definition
Pharmakon
Greek
vigilare
Latin
Drug
to be awake or alert,
to keep watch
• Is the pharmacological science related to the
detection,collection,assessment,understanding
and prevention of adverse effects particularly long
term, short term side effects of medicine.(WHO 2002).
• Post-Marketing tool.
15/1/2014
Dr. Prajeesh nath, ASA
3
4. Technical terms
Adverse Drug Reactions(ADRs) - A response to a drug
which is noxious and unintended, and which occurs at
doses normally used in man for the
prophylaxis, diagnosis, or therapy of disease, or for the
modification of physiological function.
Eg. Hypersensitivity rash with intake of guggulu
Adverse Event/Experience(AE) - Any untoward
medical occurrence that may present during treatment
with a pharmaceutical product but which does not
necessarily have a causal relationship with the
treatment.
15/1/2014
Dr. Prajeesh nath, ASA
4
5. Side Effect(SE) - Any unintended effect of a
pharmaceutical product occurring at doses normally
used in human which is related to the pharmacological
properties of the drug .
Eg. Use of Atropine in oraganophosphorus poisoning achieves
therapeutic action by its anticholinergic activity but at same time
causes dryness of mouth & dilatation of pupil which is not
noxious.
Serious Adverse Event (SAE) – Any adverse event
which is fatal, life- threatening, permanently disabling or
which results in hospitalisation.
15/1/2014
Dr. Prajeesh nath, ASA
5
6. Expected adverse reaction - As opposed to
“unexpected”, an event that is noted in the brochure or
labeling.
Unexpected adverse reaction - The nature or
severity of which is not consistent with the domestic
labeling or market authorization, or expected from
characteristics of the drug.
Signal - Reported information on possible causal
relationship between an adverse event and a drug, the
relationship being unknown or incompletely
documented previously.
Usually more than one single report is required to
generate a signal
15/1/2014
Dr. Prajeesh nath, ASA
6
7. Historical Background…
Thalidomide tragedy (1961)- greatest of all drug
disasters.
1960 marketed in 46 countries (hypnotic, prevention
of nausea in pregnancy) .
Tragically the drug proved to be a potent human
teratogen that caused major birth defects in an
estimated 20,000 children.
Phocomelia(Absence of proximal part of limbs) was
a characteristic feature.
15/1/2014
Dr. Prajeesh nath, ASA
7
8. 1962
1963
1964
15/1/2014
• Amendment to Federal
Food, drug & Cosmetic Act required both safety & efficacy
data
• British Committee on Safety of
drug monitoring
• UK starts “yellow cards” system
Dr. Prajeesh nath, ASA
8
9. 1964-65
1968
1978
15/1/2014
• National ADR reporting
system UK, Australia, New
Zealand, Canada, West
Germany, Sweden.
• WHO: Programme for
International Drug
Monitoring
• WHO center moved
from Geneva to Uppsala
Dr. Prajeesh nath, ASA
9
10. UMC(Uppsala monitoring centre)
Uppsala monitoring centre(UMC,Swedan) is a field
name of the WHO collaborating Centre for
International Drug Monitoring.
It is responsible for the management of the WHO
program for International Drug Monitoring.
UMC has >3 million AE case reportes from over 75
countries.
The data are supplied by national health authorities
Does not review or assess the individual cases put into
database, but it does pharmacovigilance analyses and
signaling.
15/1/2014
Dr. Prajeesh nath, ASA
10
11. 4 common drugs banned in other
countries but not in India
S.N
o
Drug
Use
Reason for ban
Brand name
1
Nimesulide
Pain
killer,Fever
Liver failure
Nise,
Nimulid
2
Phenylprapanolamine
Cold &
Cough
Stroke
D’cod, Vicks
Action500
3
Quiniodochlor
Antidiarrheal
Damage to
sight
Enteroquinol
4
Analgin
Pain killer
Bone marrow
depression
Novalgin
15/1/2014
Dr. Prajeesh nath, ASA
11
12. Aims of Pharmacovigilance
Improve patient care and safety.
Improve public health and safety.
To contribute to the assessment of
benefit, harm, effectiveness and risk of medicines.
To promote understanding, education and clinical
training.
15/1/2014
Dr. Prajeesh nath, ASA
12
14. Pharmacovigilance in India
1986
1997
• ADR monitoring system
for India proposed (12
regional centres)
• India joined WHO-ADR
monitoring programme
(3 centres:
AIIMS, KEM, JLN)
2010
2004 – 2008
• Pharmacovigilance
programme of India
(PvPI)
• National PV Prog. (2
Zonal, 5 Regional, 24
Peripheral) overseen by
CDSCO
15/1/2014
Dr. Prajeesh nath, ASA
14
15. Pharmacovigilance in India
PV was established since 2003 under the control of
Central Drug Standard Control Association(CDSCO)
under the aegis of Ministry of H & FW, DGHS (Directorate
General of Health Service) New Delhi.
WHO emphasized that it should include Traditional
medicines in PV system and has published guidelines
on safety monitoring of herbal medicines in
pharmacovigilance systems in 2004.
15/1/2014
Dr. Prajeesh nath, ASA
15
16. IPGT & RA ,Jamnagar conducted a two days
workshop on 3rd & 4th December 2007, on
“Pharmacovigilance for Ayurvedic Drugs:
Scope, Limitations & Methods of Implementation”.
Based on the recommendations from the
workshop, Pharmacovigilance Cell (PV Cell), has
been established .
Reporting Form for Suspected ADRs of Ayurvedic
Formulations has been developed.
15/1/2014
Dr. Prajeesh nath, ASA
16
17. National Pharmacovigilance
Programme for ASU (NPP-ASU)
ASU drugs are considered as safe drugs.
This perception is likely to change in the light of some
recent incidences of ADR during their use.
The first National Consultative meet of National
Pharmacovigilance Programme for ASU Drugs was
organized at Dept. of AYUSH, Ministry of Health &
FW, New Delhi on August 2008, sponsored by WHO.
15/1/2014
Dr. Prajeesh nath, ASA
17
18. Based on the feed back received from the
meet, National Pharmacovigilance Programme for ASU
drugs was launched on 29th Sept 2008.
The purpose of the programme is to collect and collate
data, analyse it and use the inferences to recommend
informed regulatory interventions, beside
communicating risks to healthcare professionals and
the public.
15/1/2014
Dr. Prajeesh nath, ASA
18
19. Objectives
Short-term objectives - To develop the culture of
notification.
Medium-term objectives - To involve healthcare
professionals and professional associations in the drug
monitoring and information dissemination processes.
Long-term objectives - To achieve operational efficiencies
that would make NPP for ASU drugs a benchmark for
global drug monitoring endeavours.
15/1/2014
Dr. Prajeesh nath, ASA
19
20. National PV centre
PV Centres in India
IPGT
& RA
N
TVM
Guhwat
BHU
W
NIA
15/1/2014
E
BHU
30 Pheripheral
PV centres
S
8 Regional PV
centres
C
CCR
AS
Dr. Prajeesh nath, ASA
Chennai
B’lore
Bhopal
20
22. WHAT TO REPORT?
All suspected adverse reactions.
Lack of effects.
Resistance.
Drug interactions.
Reactions suspected of causing:
a. Death
b. Life threatening (real risk of dying)
c. Hospitalisation (initial or prolonged)
d. Disability (significant, persistent or permanent)
e. Congenital anomaly
15/1/2014
Dr. Prajeesh nath, ASA
22
25. WHO CAN REPORT ?
Any health care professional can report .
Shall not accept reports from lay members of the
public.
Others can report through the physicians under whom
he / she had undergone treatment.
Consumer can directly report to the concerned PPC /
RPC / nearest health centre or physician regarding the
suspected ADR.
15/1/2014
Dr. Prajeesh nath, ASA
25
27. WHAT HAPPENS TO THE INFORMATION
SUBMITTED ?
Confidential.
PPC forward the form to the respective RPC (causality
analysis). This information shall be forwarded to
the NPRC.
The data will be statistically analysed and forwarded
to the Dept. of AYUSH
PPC
15/1/2014
RPC
NPRC
Dr. Prajeesh nath, ASA
AYUSH
27
28. RESPONSIBILITIES OF CENTRE'S
To collect ADR reports.
To fill in the ADR form properly.
To forward duly filled in ADR forms to next higher
centre.
To maintain a log of all ADR notification forms.
To provide general technical support,coordinate and
monitor the functioning of Centres.
To carry out causality analysis of all ADR forms.
15/1/2014
Dr. Prajeesh nath, ASA
28
29. To forward all duly-filled ADR forms as per
pre-determined time line.
To report all SADRs within 24 Hrs.
To forward periodic reports to next higher
centre.
To orgnize and attend training programs/
interactive meetings for all lower level
centres.
Organize the public campaigns.
15/1/2014
Dr. Prajeesh nath, ASA
29
31. Ayurvedic concept of PV
Term PV does not feature in Ayurvedic texts.
Rational drug use are reccurent themes of Ayurvedic
pharmacology(DRB) and therapeutics(chikitsa).
Along with descriptions related to actions & benefits of
medicines, Ayurvedic pharmacology describes detailed
adverse reactions & also how to deal with ways to
minimize adverse effect such as
1. Precaution in manufacture techniques.
2. Time of drug administration.
3. Compliment diet and life style and so on.
15/1/2014
Dr. Prajeesh nath, ASA
31
32.
ll(Ca.Su.
15/4)
Effectiveness of all actions depends on proper
administratoin, Conversely failure is the result of
improper administration.
-
ll (Ca. Vi.
1/15)
Of all the substances , one should not resort too much
to the 3, Pippali, Kshara, Salt
15/1/2014
Dr. Prajeesh nath, ASA
32
33. Pippali when used properly alleviates dosas,however
their excessive and continous use for long time , leads
to aggravation of dosas.
Kshara is used for
purpose but if
used excess proves harmful for hair, eyes,heart and
sexual ability. Continous use causes
.
Lavanam is used as
, but excess uses
produces
.
15/1/2014
f
Dr. Prajeesh nath, ASA
l
ll (Ca. Su. 1/124)
33
34. Need of PV for Ayurvedic Medicines
In ancient times, physicians prepared medicines for
their patients themselves.
Today production and sale of Ayurveda drugs is
formalized into a thriving industry.
Ayurvedic medicines –
1.Classical Ayurvedic formulations
2.Patent and proprietry formulations.
This industrialization has brought many challenges
about safe use of Ayurvedic medicines.
15/1/2014
Dr. Prajeesh nath, ASA
34
35. Challenges in introducing PV in Ayurveda
NPP encouraged reporting of all suspected ADRs, But
number of reports related to Ayurvedic /herbal drugs
are abnormally low.
Concept & terminologies related to ADR monitoring
are not covered in the Ayurvedic curriculum.
Methods to study drug safety problems have not
evolved adequately in Ayurveda.
Information related to medicines are in the form of
slokas in the texts, it is not easily available for general
public.
15/1/2014
Dr. Prajeesh nath, ASA
35
36. Signal detection is difficult because of inherent
belief that Ayurvedic medicines are safe.
Patients often use medicines from different
systems of medicine concomitantly - difficulty
in assigning causality.
Lack of quality assurance and control in
manufacture of Ayurvedic medicine.
Most Ayurvedic formulations are multiingredient.
15/1/2014
Dr. Prajeesh nath, ASA
36
37. Summary and Conclusion
By incoperating PV, we will be able to prepare
medicines with good efficacy,,quality, safety and
minimum harmful effect.
In all, Pharmacovigilance will promote:
Systematic and rational use of medicines
Boost confidence for safety.
15/1/2014
Dr. Prajeesh nath, ASA
37
Adverse Event (AE) – A negative experience encountered by an individual during the course of a clinical trail, which may or may not be associated with a drug
To improve patient care and safety in relation to the use of medicines, and all medical and paramedical interventions To improve public health and safety in relation to the use of medicinesTo contribute to the assessment of benefit, harm, effectiveness and risk of medicines, encouraging their safe, rational and more effective use To promote understanding, education and clinical training in pharmacovigilance and its effective communication to health professionals and the public
Perceptive of the importance of Pharmacovigilance,Institute for Post Graduate Teaching and Research In Ayurveda,Jamnagar has already conducted a two days workshop on 3rd &4th December 2007, on “Pharmacovigilance for Ayurvedic Drugs:Scope, Limitations & Methods of Implementation”, funded byWHO, Country Office for India, New Delhi. Based on therecommendations of the workshop, a Pharmacovigilance Cell(PV Cell), first of its kind in India for Ayurveda, has beenestablished and a Reporting Form for Suspected AdverseReactions of Ayurvedic Formulations has been developed anddistributed among the faculty members / research scholars /physicians under intimation to the Department of AYUSH,Ministry of Health and F.W., Govt. of India.
To put pharmacovigilance for ASU drugs in proper place in India, formation of a National Pharmacovigilance Centre for ASU Drugs, under the control of Department of AYUSH, is highly essential which would monitor the programme centrally. This programme aims to provide adverse drug reaction data related to various drugs of herbal, mineral, metallic, animal and other origin available in the country.The programme is being coordinated by NPRC-ASU under the guidance of National Pharmacovigilance Consultative Committee for ASU drugs being constituted by Department of AYUSH, Ministry of Health and FW, Govt. of India. The first National Consultative meet of National PharmacovigilanceProgramme for ASU Drugs was organized at Dept. of AYUSH, Ministry of Health & FW, New Delhi on 29th & 30th August 2008, sponsored by WHO, Country Office for India, New Delhi, where the draft protocol was technically reviewed and finalized. The finalized draft was circulated among the experts who attended the meet for their comments and additional inputs, if any. Based on the feed back received, final version of the protocol is prepared and the same is being released as a part of launching of National PharmacovigilanceProgramme.
Sponsored and coordinated by the country's National Pharmacovigilance Resource Centre (NPRC) for ASU drugs to establish and manage a data base of ADRs for making uniformed regulatory decisions regarding marketing authorisation of drugs in India for ensuring safety of drugs.
Any Health care professionals including, ASU Doctors / Dentists / Nurse / Pharmacistsetc.
The reporting on prescribed format will be done to any of the Pharmacovigilancecentres.
The information in the form shall be handled inconfidentiality. Peripheral PharmacovigilanceCentresshall forward the form to the respective RegionalPharmacovigilanceCentres who will carry out thecausality analysis. This information shall be forwarded tothe National Pharmacovigilance Resource Centre. Thedata will be statistically analysed and forwarded to theDept. of AYUSH, Govt. of India.
To collect ADR reporting To fill in the ADR form properly To forward duly-filled in ADR forms to next higher level centreTo maintain a log of all ADR notification forms (blank or filled) To identify, induce PPC / RPC (with concurrence of NPRC - ASU), provide them with general technical support,coordinate and monitor their functioningTo identify and deploy a pharmacologist for management of pharmacovigilance tasksTo identify and deploy a data manager for data management
To carry out (or review) causality analysis of all ADR forms or review such analysis by the RPCTo forward all duly-filled ADR forms as per pre-determined time line i.e. first week of every month Information of all serious ADR's must be conveyed to the NPRC within 2 working days by fax, email, telephone, courier as per stipulated guideline To report all serious adverse reactions within 24 Hrs. To forward periodic reports to next higher centre in first week of every month.To liaison with healthcare professionals order to inculcate / foster the culture of ADR reporting 1. Acknowledge the cooperation of the notifier 2. Share with notifier relevant feedback from higher centres To orgnize and attend training programs/ interactive meetings for all lower level centres Organize the public campaigns
, the spirit of PV is vibrant & is emphasized repeatedly in Samhitas.